Additional Information
Book Details
Abstract
Topics in this issue of Dermatologic Clinics include: Incidence and prevalence; Impact on quality of life; Special considerations of hyperhidrosis in children; Topical therapies; Iontophoresis; Botox for axillary hyperhidrosis; Botox for palmar/plantar hyperhidrosis; Botox for other hyperhidrosis; Systemic therapies for hyperhidrosis; Procedural approaches; Endoscopic thoracic sympathectomy; Emerging and investigative treatments; Resources for patients and physicians; Incorporating diagnosis and treatment into clinical practice. Dr David Pariser is Editor of this publication; a founding member of the International Hyperhidrosis Society and renown researcher and lecturer on mechanism, diagnosis, and treatment of hyperhidrosis, Dr Pariser continues to investigate therapies that are effective for patients.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Hyperhidrosis\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Dermatologic Clinics\r | ix | ||
| Preface\r | xi | ||
| Incidence and Prevalence of Hyperhidrosis | 457 | ||
| Key points | 457 | ||
| Introduction | 457 | ||
| Primary hyperhidrosis | 457 | ||
| Focal Sites | 458 | ||
| Hexsel’s Hyperhidrosis | 458 | ||
| Localized Unilateral Hyperhidrosis | 458 | ||
| Diagnostic Criteria for Primary Hyperhidrosis | 458 | ||
| Hyperhidrosis Prevalence | 458 | ||
| Hyperhidrosis Epidemiology | 459 | ||
| Secondary generalized hyperhidrosis | 459 | ||
| Secondary focal hyperhidrosis | 460 | ||
| Secondary regional hyperhidrosis | 463 | ||
| Summary | 463 | ||
| References | 463 | ||
| Impact of Hyperhidrosis on Quality of Life and its Assessment | 467 | ||
| Key points | 467 | ||
| Introduction | 467 | ||
| Disease-specific assessment of QoL | 468 | ||
| Hyperhidrosis Disease Severity Scale | 468 | ||
| Amir–de Campos Clinical Protocol for QoL | 469 | ||
| Hyperhidrosis Impact Questionnaire | 470 | ||
| Other Hyperhidrosis-specific Instruments | 470 | ||
| Dermatology-related assessment of QoL | 471 | ||
| Dermatology Life Quality Index | 471 | ||
| Skindex | 471 | ||
| General assessment of QoL | 471 | ||
| Short Form Health Survey (36 Item and 12 Item) | 471 | ||
| Other Instruments | 472 | ||
| Assessment of special impairments | 472 | ||
| Summary | 473 | ||
| References | 473 | ||
| Special Considerations for Children with Hyperhidrosis | 477 | ||
| Key points | 477 | ||
| Introduction | 477 | ||
| Topical therapy | 478 | ||
| Anticholinergics | 478 | ||
| Iontophoresis | 479 | ||
| Botulinum toxin | 480 | ||
| Injection Site Pain | 480 | ||
| Adverse Effects | 480 | ||
| Safety and Efficacy in Children | 481 | ||
| Surgical treatment | 481 | ||
| Liposuction | 481 | ||
| Ultrasound | 481 | ||
| Thoracic Sympathectomy | 482 | ||
| Video-Assisted Thoracoscopic Sympathectomy | 482 | ||
| Calcium-channel blockers, clonidine, α-adrenoceptor antagonists, benzodiazepine | 483 | ||
| Summary | 483 | ||
| References | 483 | ||
| Topical Therapies in Hyperhidrosis Care | 485 | ||
| Key points | 485 | ||
| Primary hyperhidrosis | 485 | ||
| The Nature of the Problem | 485 | ||
| Patient evaluation overview | 486 | ||
| Topical options for hyperhidrosis treatment | 486 | ||
| Aluminum salts | 487 | ||
| Topical glycopyrrolate | 489 | ||
| Clinical-strength OTC products | 489 | ||
| References | 490 | ||
| Iontophoresis for Palmar and Plantar Hyperhidrosis | 491 | ||
| Key points | 491 | ||
| Efficacy | 491 | ||
| Adverse events | 492 | ||
| Contraindications | 492 | ||
| Recommended regimen | 492 | ||
| References | 494 | ||
| Botulinum Toxin for Axillary Hyperhidrosis | 495 | ||
| Key points | 495 | ||
| Introduction | 495 | ||
| Botulinum toxin | 496 | ||
| Studies Comparing BoNT-A Products | 496 | ||
| Studies Comparing BoNT-A and BoNT-B Products | 497 | ||
| Toxin solution | 497 | ||
| Evaluation methods | 497 | ||
| Injection technique | 499 | ||
| Transcutaneous botulinum toxin | 500 | ||
| Summary | 502 | ||
| References | 502 | ||
| Botulinum Neurotoxin Treatment of Palmar and Plantar Hyperhidrosis | 505 | ||
| Key points | 505 | ||
| Introduction and overview | 505 | ||
| Patient evaluation | 506 | ||
| Management goals and strategy | 506 | ||
| BoNT | 507 | ||
| Evaluation of treatment and recommendations | 507 | ||
| Treatment complications | 510 | ||
| Procedure for administration of BoNT | 510 | ||
| BoNT Dilution | 510 | ||
| Multiple Needles for Injection | 510 | ||
| Iodine Starch Test | 510 | ||
| Injection Pain Reduction | 510 | ||
| Nerve Blocks | 511 | ||
| Treatment Area | 511 | ||
| Injection Dose | 513 | ||
| Injection Technique | 513 | ||
| Patient Monitoring and Followup | 513 | ||
| Summary | 513 | ||
| References | 513 | ||
| Botulinum Toxin for Hyperhidrosis of Areas Other than the Axillae and Palms/Soles | 517 | ||
| Key points | 517 | ||
| Introduction | 517 | ||
| Patient evaluation overview | 517 | ||
| Management goals and botulinum toxin preparation | 518 | ||
| Craniofacial hyperhidrosis | 518 | ||
| Frey syndrome (gustatory sweating) | 521 | ||
| Submammary hyperhidrosis | 521 | ||
| Hyperhidrosis of the groin | 522 | ||
| Hyperhidrosis of amputated limbs | 522 | ||
| Compensatory hyperhidrosis | 524 | ||
| Summary | 524 | ||
| References | 524 | ||
| Oral Medications | 527 | ||
| Key points | 527 | ||
| Introduction | 527 | ||
| Treatment indications | 527 | ||
| Anticholinergic agents | 528 | ||
| Glycopyrrolate | 528 | ||
| Oxybutynin | 529 | ||
| Other Anticholinergic Agents | 530 | ||
| Anticholinergic Use in Pediatric Patients | 530 | ||
| β-Adrenergic blockers | 530 | ||
| α-Adrenergic agonist | 531 | ||
| Benzodiazepines | 531 | ||
| Other systemic agents | 531 | ||
| Summary | 531 | ||
| References | 531 | ||
| Local Procedural Approaches for Axillary Hyperhidrosis | 533 | ||
| Key points | 533 | ||
| Introduction | 533 | ||
| Patient evaluation overview | 533 | ||
| Management goals | 534 | ||
| Surgical treatment options and procedure | 534 | ||
| Excision | 534 | ||
| Liposuction | 535 | ||
| Liposuction-Curettage | 535 | ||
| Curettage | 536 | ||
| MiraDry | 536 | ||
| Evaluation of outcome, adjustment of treatment, and long-term recommendations | 538 | ||
| Summary | 540 | ||
| References | 540 | ||
| Endoscopic Thoracic Sympathectomy | 541 | ||
| Key points | 541 | ||
| Introduction and history | 541 | ||
| Anatomy and physiology | 542 | ||
| Nomenclature | 542 | ||
| Indications | 542 | ||
| Techniques | 543 | ||
| Outcomes | 544 | ||
| Unilateral or Bilateral ETS | 544 | ||
| Bilateral ETS | 544 | ||
| Gender Differences in Outcomes of ETS | 544 | ||
| Outcomes Variances | 544 | ||
| Variation in outcomes by anatomic location of hyperhidrosis | 545 | ||
| Complications | 545 | ||
| Compensatory sweating | 546 | ||
| Quality of life | 546 | ||
| Reversal | 547 | ||
| Summary | 547 | ||
| References | 547 | ||
| Managing Hyperhidrosis | 549 | ||
| Key points | 549 | ||
| Introduction | 549 | ||
| Botulinum Toxins | 549 | ||
| Topical botulinum toxin | 549 | ||
| Topical Anticholinergics | 550 | ||
| Glycopyrrolate | 550 | ||
| Oxybutynin | 550 | ||
| Devices to Reduce Sweating | 550 | ||
| Fractional microneedle radiofrequency treatment | 550 | ||
| Long-pulsed 800 nm diode laser | 551 | ||
| 1064-nm Nd-YAG laser | 551 | ||
| Ultrasound | 551 | ||
| Externally applied ultrasound | 552 | ||
| Summary | 552 | ||
| References | 552 | ||
| Resources for Hyperhidrosis Sufferers, Patients, and Health Care Providers | 555 | ||
| Key points | 555 | ||
| Incorporating Diagnosis and Treatment of Hyperhidrosis into Clinical Practice | 565 | ||
| Key points | 565 | ||
| Best practices for patient flow | 566 | ||
| Billing and coding for hyperhidrosis and its treatments | 566 | ||
| ICD-9 Codes | 566 | ||
| ICD-10 Codes | 567 | ||
| CPT Codes | 567 | ||
| Iontophoresis | 567 | ||
| Botulinum toxin injections | 567 | ||
| HCPCS J Codes | 567 | ||
| Billing options for botulinum toxin treatments | 567 | ||
| Billing for other services relating to hyperhidrosis treatments | 573 | ||
| Summary | 574 | ||
| Index | 575 |